The U.S. Food and Drug Administration has approved the 9-valent human papillomavirus vaccine Gardasil 9 (Merck Sharp & Dohme Corp).
The vaccine covers the same four human papillomaviruses (HPVs) as Gardasil plus an additional five types known to cause approximately 20 percent of cervical cancers (HPV 31, 33, 45, 52, 58).
The course for Gardasil 9 is three immunisations over a six month period, following the same schedule as Gardasil. The vaccine has a similar safety profile to Gardasil, is equally effective for preventing disease against HPV 9, 11, 16, & 18 as Gardasil and is 97% effective in preventing vulvar and cervical cancers caused by HPV 31, 33, 45, 52, & 58. Gardasil 9 is licensed in the U.S. for females aged 9 through 26 years and males aged 9 through 15 years.
- Gardasil (protecting against HPV 9, 11, 16, & 18) is the only vaccine that protects against HPV infection in New Zealand.
- There is no information suggesting that Gardasil 9 will become available in New Zealand in the future.
- Administration of Gardasil to individuals eligible for National Immunisation Schedule vaccine or individuals who are purchasing Gardasil privately should not be delayed "in case" Gardasil 9 becomes available in New Zealand in the future.
Click on the link to read the news release on the U.S. Food and Drug Administration (FDA) website.